Immune Cell Discovery Raises Hope In India Amid Rising Glaucoma Cases

In a discovery that could reshape the understanding and treatment of glaucoma — one of the leading causes of irreversible blindness in India as well as in the world — scientists have identified a previously unknown role played by immune cells in maintaining eye pressure, a key factor in preventing vision loss from the disease.

Glaucoma is a group of eye disorders that damage the optic nerve, the structure responsible for transmitting visual signals from the eye to the brain. The condition is often associated with increased intraocular pressure (IOP), although damage can occur even in individuals with normal eye pressure.

Researchers from the Duke University School of Medicine tracked fluorescently tagged immune cells — known as resident macrophages — in mouse eyes. When they selectively removed these cells, the eye’s drain became clogged, fluid built up, and eye pressure increased.

“The only way we can treat glaucoma is by lowering the eye pressure, yet we still have patients who go blind despite current treatments,” said the lead author of the study and assistant professor in the Department of Ophthalmology at Duke University School of Medicine.

“This research helps us understand the role of the immune system in regulating eye pressure,” Liu said, adding that the findings could pave the way for new therapies to protect the optic nerve and slow the progression of glaucoma.

The study is published in the journal Immunity.

Current treatments for glaucoma primarily focus on lowering intraocular pressure through medications, laser procedures, or surgery. However, these treatments mainly address the symptoms rather than the underlying cause of the disease.

For India, where glaucoma remains a major public health challenge, with nearly 12 million people affected by the eye condition according to estimates, such advances could prove transformative as researchers plan to conduct studies on humans.

Known as the ‘silent thief of vision,’ glaucoma leaves millions undiagnosed until the disease has already caused substantial and irreversible vision loss.

Because the disease progresses silently over many years, many patients in India seek medical care only when vision loss has already begun. Even among patients undergoing treatment, doctors sometimes observe continued optic nerve damage despite apparently controlled eye pressure.

Speaking about the implications of the research, Dr. Suneeta Dubey, Medical Director and Head of Glaucoma Services at Dr. Shroff’s Charity Eye Hospital, said the findings highlight the importance of continued research and early diagnosis.

“If confirmed in human studies, this discovery could open the door to innovative treatments that enhance or restore the activity of these immune cells, helping maintain proper drainage in the eye and preventing the onset of glaucoma,” she said.

Dr. Dubey stated that “an exciting new frontier in glaucoma research represents the intersection of immunology and ophthalmology.” With its large population, diverse genetic profile, and expanding research ecosystem, India has significant potential to contribute to advances in this emerging field, she added.

While new research offers hope for better treatments in the future, experts emphasise that currently early detection remains the most effective strategy for preventing vision loss.

“Glaucoma often develops gradually and without noticeable symptoms, which is why many patients remain undiagnosed until irreversible damage has occurred,” Dr. Dubey noted. “Regular eye examinations, especially after the age of 40, are essential for early detection and preserving vision.”

These concerns were also highlighted during a glaucoma awareness conclave organised in the national capital on the occasion of World Glaucoma Week, where leading ophthalmologists stressed the urgent need to increase public awareness and screening.

“Glaucoma is often called the ‘silent thief of sight’ because many patients remain unaware of the disease until significant vision loss has already occurred,” said Suresh Pattathil, Managing Director and General Manager of AbbVie India. “Through initiatives like this conclave, we aim to strengthen awareness about early detection and encourage regular eye examinations.”

Experts at the discussion also stressed the importance of routine screening and long-term management.

Dr. Harsh Kumar, a cataract and glaucoma specialist at Centre for Sight, noted that comprehensive eye examinations — including optic nerve evaluation and measurement of intraocular pressure — can help detect glaucoma at an early stage.

“With early diagnosis and appropriate management, the progression of the disease can often be slowed significantly,” he said.

Dr. Ramanjit Sihota of Shroff Eye Centre emphasised that glaucoma requires lifelong monitoring and adherence to treatment.

“Glaucoma management requires lifelong monitoring and adherence to treatment. Increasing public awareness and encouraging timely consultations with eye specialists can help prevent irreversible vision loss,” she said.

Moderating the discussion, Dr. Deven Tuli, Glaucoma Specialist at Netram Eye Foundation, underscored the need for collaborative action.

“Addressing glaucoma requires a collective approach involving clinicians, policymakers, and the public. Strengthening awareness and improving access to screening and treatment services will be critical in reducing glaucoma-related blindness in India.”